US Stock MarketDetailed Quotes

PHVS Pharvaris

Watchlist
  • 17.270
  • -0.100-0.58%
Close Feb 14 16:00 ET
  • 17.270
  • 0.0000.00%
Post 16:00 ET
936.61MMarket Cap-6.33P/E (TTM)

About Pharvaris Company

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Company Profile

SymbolPHVS
Company NamePharvaris
Listing DateFeb 5, 2021
Issue Price20.00
Founded2015
CEOMr. Berndt Modig
MarketNASDAQ
Employees82
Fiscal Year Ends12-31
AddressEmmy Noetherweg 2
CityLeiden
ProvinceZuid-Holland
CountryNetherlands (the)
Zip Code2333 BK
Phone31-71-203-64-10

Company Executives

  • Name
  • Position
  • Salary
  • Berndt Modig
  • Chief Executive Officer and Executive Director
  • 935.28K
  • Dr. Morgan Conn, PhD
  • Chief Business Officer
  • --
  • Joan Schmidt
  • Chief Legal Officer
  • --
  • Annick Deschoolmeester
  • Chief Human Resources Officer
  • --
  • Dr. Wim Souverijns, PhD
  • Chief Community Engagement and Commercial Officer
  • --
  • Dr. Stefan Abele, PhD
  • Chief Technical Operations Officer
  • --
  • Dr. Peng Lu, M.D.,PhD
  • Chief Medical Officer
  • --
  • Dr. Anne Lesage, PhD
  • Chief Early Development Officer
  • --
  • Anna Nijdam, M.Sc.
  • Head of Strategic Finance and Principal Accounting Officer
  • --
  • Dr. David P. Meeker,M.D.
  • Independent Director
  • 94.00K
  • Viviane Monges
  • Independent Director
  • 62.50K
  • Hans Schikan, Pharm.D.
  • Independent Director
  • 61.00K
  • Dr. Robert Glassman, M.D.
  • Independent Director
  • 50.50K
  • Dr. Elisabeth Bjork, M.D.,PhD
  • Independent Director
  • 45.00K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More